guanidine has been researched along with etoposide in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Titulaer, MJ; van Gerven, J; Verschuuren, JJ; Willems, LN; Wirtz, PW | 1 |
Chakraborty, A; De, A; Patravale, V; Pawar, Y; Sable, S; Selkar, N; Shete, H; Tidke, P; Vanage, G | 1 |
2 review(s) available for guanidine and etoposide
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Antineoplastic Agents; Carcinoma, Small Cell; Cholinesterase Inhibitors; Cisplatin; Etoposide; Guanidine; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Immunotherapy; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Parasympathomimetics; Plasmapheresis; Potassium Channel Blockers; Prednisolone; Pyridostigmine Bromide; Randomized Controlled Trials as Topic | 2006 |
1 other study(ies) available for guanidine and etoposide
Article | Year |
---|---|
Mono-guanidine heterolipid based SMEDDS: A promising tool for cytosolic delivery of antineoplastics.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Emulsions; Etoposide; Female; Guanidine; Lipids; Melanoma; Mice, Inbred C57BL; Solubility | 2015 |